Ryoichi Onozato
Overview
Explore the profile of Ryoichi Onozato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
679
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang X, Liu W, Edaki K, Nakazawa Y, Kamioka H, Fujita A, et al.
Can J Infect Dis Med Microbiol
. 2021 Dec;
2021:4005327.
PMID: 34876945
Multidrug resistance (MDR) due to enhanced drug efflux activity of tumor cells can severely impact the efficacy of antitumor therapies. We recently showed that increased activity of the efflux transporter...
2.
Imai H, Onozato R, Kaira K, Kawashima S, Masubuchi K, Tajima K, et al.
Oncology
. 2021 Nov;
100(2):89-100.
PMID: 34844253
Introduction: In stage I-III non-small cell lung cancer (NSCLC), which is considered operable, surgical resection is the most efficacious treatment and is considered to provide a cure. However, after complete...
3.
Imai H, Onozato R, Kaira K, Kawashima S, Masubuchi K, Nagashima T, et al.
Thorac Cancer
. 2021 Sep;
12(20):2740-2748.
PMID: 34477313
Background: For early-stage non-small cell lung cancer (NSCLC), surgical resection is considered the most effective treatment strategy and curative treatment. Unfortunately, even after complete resection, almost half of all patients...
4.
Ohtaki Y, Kaira K, Yajima T, Erkhem-Ochir B, Kawashima O, Kamiyoshihara M, et al.
Thorac Cancer
. 2021 Aug;
12(20):2666-2679.
PMID: 34453496
Objectives: Various drug-sensitivity markers have been reported to be associated with tumor progression and chemotherapy resistance. Detailed expression profiles of sensitivity markers for cytotoxic chemotherapy in pulmonary large cell neuroendocrine...
5.
Imai H, Onozato R, Ginnan M, Kobayashi D, Kaira K, Minato K
Medicina (Kaunas)
. 2021 Jun;
57(5).
PMID: 34069436
: Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitizing epidermal growth factor receptor () mutations show a good response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). The subsequent treatments influence the...
6.
Kotake M, Imai H, Onozato R, Fujita A, Fujisawa T, Nakazato Y, et al.
Mol Clin Oncol
. 2020 Sep;
13(5):53.
PMID: 32874583
Breast metastases of primary lung neuroendocrine tumors are rarely reported. The current report presents the case of a 41-year old female with no history of smoking who initially underwent surgery...
7.
Kamioka H, Tomono T, Fujita A, Onozato R, Iijima M, Tsuchida S, et al.
J Pharm Sci
. 2020 Mar;
109(7):2302-2308.
PMID: 32173323
Epithelial-mesenchymal transition (EMT) plays a role in not only cancer metastasis, but also drug resistance, which is associated with increased levels of efflux transporters such as P-glycoprotein (P-gp). Here, we...
8.
Kosaka T, Yajima T, Yamaki E, Nakazawa S, Tomizawa K, Onozato R, et al.
Mol Clin Oncol
. 2019 Aug;
11(3):309-312.
PMID: 31396389
gene rearrangements are identified in approximately 5% of patients with non-small cell lung cancer (NSCLC). Despite initial dramatic responses to ALK inhibitors, the majority of patients relapse within 1 year,...
9.
Yajima T, Hoshino K, Muranushi R, Mogi A, Onozato R, Yamaki E, et al.
Mol Immunol
. 2019 Feb;
107:97-105.
PMID: 30711908
Antigen (Ag)-specific activated CD8 T cells are critical for tumor elimination but become exhausted, and thus, dysfunctional during immune response against the tumor due to chronic antigen stimulation. The signaling...
10.
Ohtaki Y, Kaira K, Atsumi J, Nagashima T, Kawashima O, Ibe T, et al.
Am J Transl Res
. 2018 Nov;
10(10):3243-3253.
PMID: 30416665
Objectives: Since large cell neuroendocrine carcinoma (LCNEC) is a relatively rare histologic type of primary lung cancer, little is known about the immunological status of patients with LCNEC. We aimed...